Abstract
Objective: To survey the level of vWF VCAM-1, MCP-1, D-Dimer and evaluate the clinical severity prognosis of vWF, VCAM-1, MCP-1, D-dimer biomarker complex in acute ischemic stroke. Subjects and methods: A cross-sectional descriptive study, which compares between 50 patients of acute ischemic stroke and 40 healthy controls. Results: 1. The average concentration of vWF, VCAM-1, MCP-1, D-Dimer of acute ischemic stroke and controled groups were: vWF 177.80 ± 6.90MU/ml patient/148.98±19.04MU/ml control; VCAM-1 53.79±3.33ng/ml patient/43.91 ± 4.77 control; MCP-1 357.37 ± 111.03pg/ml patient/190.80 ± 51.6 pg/ml control, and D-Dimer 1016.72 ± 524.06ng/ml patient, 329.40 ± 90.16ng/ml control, p<0.001. 2. The vWF, VCAM-1, MCP-1, D-Dimer biomarker complex had a high value in prediction of clinical severity level and clinical severity progression after 48 hours of symptom onset of acute iskemic stroke. The prognostic value of clinical severity progression after 48 hours was the highest with 81.61% sensitivity, 81.42% specificity, 77.17% positive predictive value, 85.19% negative predictive value, p> 0.001, OR = 19.44. Conclusion: Concentrations of vWF, VCAM-1, MCP-1, D-Dimer increased in patients with acute ischemic stroke. The vWF, VCAM-1, MCP1, D-Dimer biomarker complex had a high value in prognosis with high sensitivity and high specificity.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call